* Prelude Therapeutics Inc PRLD.OQ reported a quarterly
adjusted
loss of 42 cents per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -58 cents. The mean expectation of
four analysts for the quarter was for a loss of 48 cents per
share. Wall Street expected results to range from -55 cents
to -44 cents per share.
* Reported revenue was zero; analysts expected zero.
* Prelude Therapeutics Inc's reported EPS for the quarter
was a
loss of 42 cents.
* The company reported a quarterly loss of $31.43 million.
* Prelude Therapeutics Inc shares had fallen by 19.2% this
quarter and lost 10.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 385%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"
Wall Street's median 12-month price target for Prelude
Therapeutics Inc is $5.00
This summary was machine generated from LSEG data May 7 at 12:02
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.48 -0.42 Beat
Dec. 31 2023 -0.49 -0.46 Beat
Sep. 30 2023 -0.58 -0.45 Beat
Jun. 30 2023 -0.63 -0.54 Beat